Latest News

Sabinsa, a pioneer in the nutraceutical and cosmeceutical industry, has provided documentation to appropriate government agencies in its continuing efforts to identify and remove adulterated vitamin C additives from the market, a practice to which Sabinsa alerted the industry earlier this year.

Sabinsa has provided FDA and FTC with documentation concerning an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants. In addition to false marketing, this undocumented additive may be considered adulteration under the Food, Drug & Cosmetic Act.

Last June, Sabinsa warned about a growing prevalence of products falsely purporting to contain vitamin C derived from amla. In fact, it has been established that amla contains only trace amounts of ascorbic acid. Instead of ascorbic acid, amla’s antioxidant properties are attributable to certain gallic acid esters (β-glucogallin and mucic acid 1,4-lactone 5-O-gallate). For example, Saberry®, Sabinsa’s proprietary amla extract, contains a minimum of 10% β-glucogallin and gallates, but only trace amounts of ascorbic acid. Although it was once thought that amla may contain high levels of ascorbic acid, those claims were later shown to be erroneous.

Since 1995, isotope ratio mass spectrometry (IRMS) has been used to detect extraneously added vitamin C in fruit juices and other products, and to identify those “spiked” with biosynthetic vitamin C.

IRMS can be used to determine a substance’s 13C/12C isotopic ratio, referred to as its δ13C value. The great majority of plants, which use C3 photosynthesis, have δ13C values between –22‰ and –30‰. On the other hand, plants which use C4 photosynthesis — including corn, sugar cane, and sorghum — have δ13C values between –8‰ and –13‰.

Because amla is a C3 plant, adulteration of “pure” amla extract with inexpensive, biosynthetic vitamin C from sugars from C4 plants like corn is readily identifiable through IRMS.

Sabinsa has become aware of a number of beverage additives and supplements which falsely claim to contain high levels of amla-based vitamin C. Such products appear to be “spiked” with inexpensive vitamin C derived from corn or other C4 plant. Such adulterated, mislabeled products may violate the FD&C Act, the FTC Act, as well as state and federal consumer protection laws.

“Sabinsa is working to bring such products to the attention of appropriate government agencies, and we urge the industry to exercise caution when purchasing ‘natural’ vitamin C additives and supplements,” said Dr. Muhammed Majeed, founder and chairman of Sabinsa. “Absent independent IRMS analysis confirming the authenticity of such materials, they may be adulterated with biosynthetic vitamin C. This is especially a concern with purportedly ‘pure’ amla-based vitamin C additives. Because amla contains only trace amounts of vitamin C, such products are likely adulterated with vitamin C from other sources.”

Sabinsa, a pioneer in nutraceutical and cosmeceutical industry, is offering glyphosate test results to customers, using a proprietary method for testing glyphosate developed by scientists at parent company Sami-Sabinsa. In October they began testing for residual herbicide in 20 nutraceutical ingredients as a routine practice, along with all other USP listed pesticides, and are widening the scope to all products the company sells. Spices must be below 7 ppm and herbs below 0.2 ppm.

“The method development of these products is very challenging and time consuming, requiring skilled techniques,” said Sabinsa founder and chairman Dr. Muhammed Majeed. “Given Sabinsa’s mission to improve human health, confirming purity of the materials we sell makes sense.”

Glyphosate, which Monsanto patented in the mid-1970’s and sells under the name RoundUp is common, and controversial. Glyphosate is a widely used herbicide that controls broadleaf weeds and grasses, and has been registered as a pesticide in the U.S. since 1974. It is also used to dry crops out before harvesting, speeding up maturation. It is often used with GMO crops, many of which were designed to withstand its toxicity.

Initial industry testing reported a low toxicity for Glyphosate in mammals, leading regulatory authorities worldwide to set high acceptable exposure limits. However, in the intervening years, new information has raised profound concerns with many organizations and consumers as to its safety. In addition to cancer causing properties, it kills honeybees, the world’s most important crop pollinators, by reducing their gut bacteria, leaving them vulnerable to pathogens and premature death.

Multiple organizations, such as the WHO’s International Agency for Research of Cancer have stated that it is carcinogenic to humans, and there have been multi-million-dollar awards in lawsuits against the company for cancer found to be from exposure to that material. Monsanto is now owned by Bayer.

The residue definition for glyphosate in wheat for the US and the EU requires measuring the amount of glyphosate in the product. Codex, on the other hand, requires also measuring the amount of N-acetylglyphosate, which is a metabolite of glyphosate; Australia requires glyphosate, N-acetylglyphosate, and AMPA (another metabolite). Sabinsa analyses both Glyphosate and also its major metabolite AMPA. The total of these two is reported as Glyphosate. Glyphosate rapidly gets converted to AMPA after absorption in soil, which is why Sabinsa’s scientists decided to monitor AMPA as well.

Sabinsa, a pioneer in the nutraceutical and cosmeceutical industries, has expanded its large portfolio of intellectual property with a new patent granted in Mexico for the company’s Boswellia serrata ingredient Boswellin® PS.

This patent, MX328842, is for a synergistic composition containing boswellic acids and polysaccharides obtained from the Boswellia species for its property to downregulate pro-inflammatory markers. This includes, for example, PGE2, which drives the inflammatory process in different diseases.

“Inflammation is an underlying cause of many health conditions throughout the world,” said Dr. Muhammed Majeed, founder and chairman of Sabinsa. “By applying modern research to ancient Ayurvedic knowledge Sabinsa has been able to provide natural solutions, including the Boswellin PS ingredient, to this common condition.”

This property of the composition was also awarded with a patent grant in Australia, Canada, Eurasia and Taiwan.

Sabinsa, a pioneer in nutraceutical and cosmeceutical industry, has strengthened its market position in Canada with the grant of three new patents. The company has also received an additional Natural Products Number (NPN) issued by Health Canada, bringing their total number of products with health claims in Canada to 37.

Patent CA2976689 is for an invention for a water-soluble form of Curcumin, which Sabinsa sells under the brand named uC3 Clear®. The patent discloses a method of solubilizing curcuminoids using polyvinyl pyrrolidone and sodium bis (2-ethylhexyl) sulfosuccinate. The aqueous solubility of curcumin/curcuminoid mixtures is enhanced to more than 10%-15% w/v in water. Sabinsa developed this product to solve solubility challenges with use of curcumin in functional beverages.

Another new patent, CA2979287, is for the anti-cancer properties of a compound - (E)-4-(3’, 4’-Dimethoxyphenyl) but-1,3-diene (DMBPD), isolated from Thai ginger (Zingiber cassumunar). The patent discloses a concentration-dependent in-vitro anti-tumorigenic activity of (E)-1-(3,4-dimethoxyphenyl) butadiene on cancer cells (pancreatic, prostate and ovarian carcinoma). Further, the unique ability of DMPBD to cause significant decrease in the expression of cell adhesion molecules (P-selectin, E-selectin and L-selectin) as evaluated by flow cytometric studies on pancreatic carcinoma cells, points to the molecule’s specific function as an anti-metastatic agent. This invention has also been granted patents in the USA (US 9,833,422, US 9,913,809), Australia (AU2016385393), Russia (RU2694053), New Zealand (NZ735027) and Japan (JP 6584526).

The third new patent granted in Canada (CA2975170) is on the use of OLEPENT® cosmetic peptides in maintaining water hydration by increasing the expression of a water channel protein called aquaporin 5 (AQP5). The patent describes the increase in expression of genes and associated proteins for improving skin barrier function in hydration deficient human skin, using OLEPENT®. The idea of using peptides for cosmetic applications stems from the fact that the body has naturally occurring peptides that are instrumental in stimulating the healing process and controlling the signs of skin ageing. One such peptide is the C-terminal fragment of collagen 1, which constitutes the peptide Lys-Thr-Thr-Lys-Ser and can stimulate the synthesis of collagen. Sabinsa’s R&D scientists linked this peptide with oleanolic acid, which has beneficial pro-aging effects. It showed significantly better pro-aging properties like elastase inhibition and collagenase inhibition, than the individual ingredients, making it a promising combination.

Sabinsa also attained an NPN for its uC3 CLEAR composition for the Canadian Natural Health Products market with these claims:

  • Provides antioxidants for maintenance of good health
  • Used in herbal medicine to help relieve joint inflammation

“Our commitment to research and development is continuing to bring innovations that consumers can soon enjoy,” said Sabinsa Founder and Chairman Dr. Muhammed Majeed. “These patents provide the added assurance that low quality copycats won’t easily disrupt the marketplace, which protects our customers.”

Disruptions from the COVID-19 pandemic have caused hardship across the world, with the poorest people in India hit particularly hard. With the objective of helping to alleviate food insecurity, the Dr. Majeed Foundation gave 5,500 rice bags of 10 kilo each to the people of Magadi, Karnataka on September 24, 2020. The Foundation is the philanthropic organization started and funded by the Sami-Sabinsa Group founder and chairman, Dr. Muhammed Majeed.

The event was organized in partnership with the Kempegowda Development Committee. Mr. Madhu Subramanian, Director, Sami-Sabinsa Group, and State President Dr. H.M. Krishnamurthy, Kempegowda Development Committee, inaugurated the event and participated in the distribution.

“The poorest people in India have been hardest hit during this pandemic, so I wanted to help” said Dr. Majeed. “While many of the Foundation’s programs are focused upon helping poor children receive an education so they have a brighter future, right now they are just trying to survive. I’m glad to be able to help these families.”

More than 5,000 people benefitted from the event.

Dr. Majeed Foundation Distributes 5,500 Rice Bags to Needy Communities in Karnataka, IndiaFrom L to R : Dr. H.M. Krishnamurthy, State President, Kempegowda Development Committee, Mr. Madhu Subramanian, Director, Sami-Sabinsa Group, Mr. Gangadhara Murthy, Vice President - HR, Sami-Sabinsa Group, Mr. Mohammed Sharief, Director, MM Corporate Security Services, Sri. Kempegowda, Director, Kempegowda Development Committee and Sri. D.C. Siddaraju, Honorary Secretary, Kempegowda Development Committee at the food distribution event at Magadi, Karnataka organized jointly by Sami-Sabinsa Group and Kempegowda Development Committee on September 24, 2020


Dr. Majeed Foundation Distributes 5,500 Rice Bags to Needy Communities in Karnataka, IndiaBeneficiaries of the 10 kg rice bags distributed by the Dr. Majeed Foundation at Magadi, Karnataka

    VISIT US

  • Sabinsa Poland Sp. z o.o.
    Ul. Magazynowa 16
    62-030 Lubon
    Poland

  • +48 61 415 6625
  • +48 61 424 1036
  • info@sabinsa.com.pl

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.